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Stimulation of soluble guanylate cyclase slows progression in
anti-thy1-induced chronic glomerulosclerosis.
Background. A critical role of soluble guanylate cyclase and
nitric oxide–dependent cyclic 3′,5′-guanosine monophosphate
(cGMP) production for glomerular matrix expansion has re-
cently been documented in a rat model of acute anti-thy1
glomerulonephritis. The present study analyzes the renal ac-
tivity of the nitric oxide-cGMP signaling cascade in and the
effect of the specific soluble guanylate cyclase stimulator Bay
41-2272 on a progressive model of anti-thy1-induced chronic
glomerulosclerosis.
Methods. Anti-thy1 glomerulosclerosis was induced by in-
jection of anti-thy1 antibody into uninephrectomized rats. One
week after disease induction, animals were randomly assigned
to chronic glomerulosclerosis, chronic glomerulosclerosis plus
Bay 41-2272 (10 mg/kg body weight/day) or chronic glomeru-
losclerosis plus hydralazine (15 mg/kg body weight/day). In
week 16, analysis included effects on systolic blood pressure,
proteinuria, kidney function, glomerular and tubulointersti-
tial matrix protein accumulation, expression of transforming
growth factor-b1 (TGF-b1), fibronectin and plasminogen ac-
tivator inhibitor type 1 (PAI-1), macrophage infiltration, cell
proliferation, basal and nitric oxide–stimulated cGMP produc-
tion as well as tubulointerstitial mRNA expression of alpha 1
and beta 1 soluble guanylate cyclase.
Results. The moderately elevated systolic blood pressure
seen in the chronic glomerulosclerosis group was compa-
rably decreased by both treatments. Compared to normal
controls, soluble guanylate cyclase mRNA expression and ni-
tric oxide–stimulated cGMP production were up-regulated in
the tubulointerstitium of the untreated chronic glomeruloscle-
rosis animals, while its activity was decreased in glomeruli.
Bay 41-2272 treatment enhanced glomerular and tubuloint-
erstitial nitric oxide–cGMP signaling significantly. This went
along with markedly reduced glomerular and tubulointer-
stitial macrophage infiltration, number of proliferating cells,
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matrix expression and accumulation, as well as improved kid-
ney function. In contrast, hydralazine therapy did not signif-
icantly affect renal nitric oxide–cGMP signaling, macrophage
number, cell proliferation, matrix protein expression and
accumulation.
Conclusion. Glomerular and tubulointerstitial soluble
guanylate cyclase activity are discordantly altered in anti-
thy1-induced chronic glomerulosclerosis. Stimulation of soluble
guanylate cyclase signaling by Bay 41-2272 limits the progres-
sive course of this model toward tubulointerstitial fibrosis and
impaired renal function at least in part in a blood pressure–
independent manner. The results suggest that soluble guany-
late cyclase activation counteracts fibrosis and progression in
chronic renal disease.
Pathologic expansion of extracellular matrix proteins
is a hallmark of acute and chronic kidney diseases [1].
In both, matrix accumulation results from an orches-
trated increase in the production of matrix proteins such
as collagens, fibronectin, and biglycan and decrease in
matrix protein degradation by increased expression of
protease inhibitors such as plasminogen activator in-
hibitor type 1 (PAI)-1 and tissue inhibitors of metallo-
proteinases (TIMPs) [2]. Overexpression of the cytokine
transforming growth factor-b (TGF-b) has been identi-
fied as key marker and mediator of tissue matrix accumu-
lation whereever it occurs, including acute and chronic
models of renal fibrosis [3, 4]. While in acute renal dis-
eases, TGF-b expression returns to normal and matrix
accumulation resolves, TGF-b overexpression persists in
chronic renal disease and is closely related to progressive
matrix expansion and subsequent impairment of renal
function [2]. In the progression of chronic renal disease,
it is in particular the degree of tubulointerstitial injury and
fibrosis that correlates that best with the ongoing loss of
kidney function [1, 5]. Since this correlation is seen inde-
pendently of whether the underlying disease is diabetes,
hypertension, or glomerulonephritis, it is assumed that a
common final pathway is operating in the progression of
chronic renal disease.
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In acute anti-thy1 glomerulonephritis, a rat model of
acute, reversible glomerular matrix expansion, we have
recently shown that the expression and activity of the
soluble guanylate cyclase [guanosine triphosphate (GTP)
pyrophosphate-lyase (cycling) EC 4.6.1.2] is markedly up
regulated during its repair phase and that pharmacologic
soluble guanylate cyclase stimulation by Bay 41-2272
significantly limited TGF-b overproduction and matrix
expansion following the injection of anti-thy1 antibody
[6]. The enzyme soluble guanylate cyclase represents the
principal physiologic target for the freely diffusible signal
molecule nitric oxide and serves as its main downstream
signaling pathway via generation of cyclic 3′,5′-guanosine
monophosphate (cGMP) as second messenger [7, 8]. The
pyrazolopyridine derivate Bay 41-2272 is a novel drug
that specifically enhances soluble guanylate cyclase ac-
tivity by amplifying cGMP production several times in
the presence of given nitric oxide concentrations as well
as by a direct action independent of nitric oxide [9, 10].
In the kidney, soluble guanylate cyclase is predomi-
nately expressed as alpha 1, beta 1 heterodimer in mesan-
gial cells, podocytes, cortical and interstitial fibroblasts as
well as along the renal vasculature [11, 12]. Nitric ox-
ide, mainly produced by endothelially located nitric ox-
ide synthases (eNOS), activates soluble guanylate cyclase
activity by binding to its prosthetic haem groups and a
subsequent change in the transformational protein con-
formation [7]. Increasing concentrations of cGMP then
regulate further downstream effector mechanisms such
as cGMP-dependent protein kinases, cGMP-gated ion
channels, and cGMP-regulated phosphodiesterases to fi-
nally produce nitric oxide’s critical biologic effects on vas-
cular tone, platelet aggregation, and leukocyte recruit-
ment [8, 10].
The results in acute anti-thy1 glomerulonephritis sug-
gest that activation of the soluble guanylate cyclase
enzyme und subsequent cGMP generation represent an
important antifibrotic mechanism in renal disease [6]. In
order to extend these findings from acute to chronic kid-
ney matrix accumulation, this study was designed to char-
acterize the role of the renal nitric oxide–cGMP signaling
cascade in the corresponding anti-thy1–induced, progres-
sive model of chronic glomerulosclerosis. In this model,
a single injection of anti-thy1 antibody into uninephrec-
tomized rats leads to a short antibody-mediated glomeru-
lonephritis, which then progresses autonomously toward
persistent glomerulosclerosis, marked tubulointerstitial
fibrosis, and renal insufficiency over several months [13,
14]. Sixteen weeks after disease induction, the mRNA ex-
pression of soluble guanylate cyclase and the basal and
nitric oxide–stimulated cGMP production of renal tis-
sues were analyzed to characterize nitric oxide–cGMP
signaling. In addition, animals with anti-thy1–induced
chronic glomerulosclerosis were treated with the solu-
ble guanylate cyclase stimulator Bay 41-2272 or the sole
vasodilator hydralazine side by side, in doses yielding
comparable blood pressure reductions. Treatments were
started 1 week after disease induction, and in week 16, the
effects of Bay 41-2272 and hydralazine treatment on pro-
teinuria, blood pressure, renal soluble guanylate cyclase
expression and activity, glomerular and tubulointerstitial
fibrosis, and kidney function were determined.
METHODS
Materials
Unless otherwise indicated, materials, chemicals or
culture media were purchased from Sigma Chemical-
Aldrich Co. (Taufkirchen, Germany).
Animals
Male Wistar rats (150 to 180 g) were obtained from
Charles River (Sulzfeld, Germany) and fed a normal pro-
tein diet (22.5% protein) (Altromin, Lage, Germany) for
at least 3 days before the start of the experiment to al-
low equilibration. Body weight was determined weekly.
Food and water intakes were monitored daily. Animals
were housed in a constant temperature room with a 12-
hour dark/12-hour light cycle. Animal care and treatment
were in conformity with the guidelines of the American
Physiological Society and approved by local authorities.
Model of anti-thy1–induced chronic glomerulosclerosis
Anti-thy1–induced chronic glomerulosclerosis was in-
duced by surgically removing one kidney and intra-
venously injecting the monoclonal antibody 1-22-3 [5
mg/kg body weight in phosphate-buffered saline (PBS),
pH 7.4] 3 days later [13, 15]. The antibody was pro-
duced from hybridoma cell lines as previously described.
Monoclonal antibody 1-22-3 antibody binds to a thy1-
like antigen on the surface of mesangial cells of the kid-
ney and causes a fast complement- and nitric-dependent
mesangial cell lysis within the next 24 hours [13, 15]. The
progression in the anti-thy1–induced model of chronic
glomerulosclerosis is linked to the uninephrectomy that is
performed prior to anti-thy1 antibody injection, since the
glomerular disease resolves over approximately 4 weeks
in animals with two kidneys [13, 16]. To avoid interference
with the induction of disease, treatment with Bay 41-2272
or hydralazine was started 7 days after antibody injection.
Control animals with and without uninephrectomy were
injected with equal volumes of PBS only.
Drug administration
Chemically, Bay 41-2272 is 5-cyclopropyl-2- [1-
(2-fluoro-benzyl)-1H-pyrazolo [3,4-b]pyridin-3-yl]-
pyrimidin-4-ylamine. It belongs to a new class of drugs
called soluble guanylate cyclase enhancers or soluble
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guanylate cyclase stimulators [9]. Bay 41-2272 is orally
applicable and does not inhibit the activity of the cGMP-
degrading phosphodiesterase-5 [9]. In our experiments,
Bay 41-2272 was given with the food in a dose of 10
mg/kg body weight/day. This dose has previously been
reported to reduce sufficiently the mean arterial blood
pressure in spontaneously hypertensive rats [9]. Bay
41-2272 was generously provided by Dr. Johannes-Peter
Stasch (Pharma Research Center, BayerAG, Wuppertal,
Germany). The drug-containing food was produced in
our laboratory by using the flour of the standard rat
chow (22.5% protein) (A1311) (Altromin) as previously
described [17]. Briefly, Bay 41-2272 was mixed into
the dry food flour in appropriate amounts, water was
added to form pellets, and the air-dried pellets were
subsequently given to the animals.
Hydralazine was given with the drinking water target-
ing a dose of 15 mg/kg body weight/day. Although the
precise mechanism of action is not fully understood, hy-
dralazine lowers blood pressure by directly relaxing vas-
cular smooth muscle cells and thereby exerting peripheral
vasodilation [18]. This effect may involve an inhibition of
the Ca2+ release from the sarcoplasmic reticulum [18].
Experimental groups and design
A 24-hour urine was collected 1 week after anti-
thy1 antibody injection. On the basis of the actual
24-hour proteinuria achieved, the nephritic animals
were randomly assigned to the following groups:
(1) uninephrectomized, anti-thy1–injected animals, no
treatment [chronic glomerulosclerosis (N = 18)]; (2)
uninephrectomized, anti-thy1–injected animals treated
with Bay 41-2272 [chronic glomerulosclerosis + Bay
41-2272 (N = 18)]; and (3) uninephrectomized, anti-
thy1–injected animals treated with hydralazine [chronic
glomerulosclerosis + hydralazine (N = 12)]. In addition,
groups of nonnephrectomized, PBS-injected controls
[two-kidney control (N = 5)] and uninephrectomized,
PBS-injected controls [one-kidney control (N = 4)] were
included.
In week 16 (i.e., after 15 weeks of Bay 41-2272 and
hydralazine treatment), effects on proteinuria, blood
pressure, renal soluble guanylate cyclase activity, tis-
sue fibrosis, macrophage infiltration, cell proliferation,
and kidney function were determined. Glomerular
and tubulointerstitial changes were analyzed separately.
Glomeruli were isolated by a graded sieving technique.
Since renal cortex consists mainly of tubulointerstitial
tissue (>95%), it was used as representative for the
tubulointerstitium. Soluble guanylate cyclase signaling
was analyzed by the mRNA expression of alpha 1 and
beta 1 soluble guanylate cyclase and by the cGMP
production of renal tissues ex vivo in response to a
defined nitric oxide stimulus. Analysis of fibrosis in-
volved a computer-based histologic calculation of the
matrix actually accumulated and molecular analysis of
the expression of the key fibrosis marker and mediator
TGF-b1, the matrix protein fibronectin indicating ma-
trix protein synthesis and the protease inhibitor PAI-1
indicating matrix protein degradation. Tubulointerstitial
and glomerular macrophage infiltration and cell prolif-
eration were analyzed by immunohistochemistry using
an ED1 or a proliferating cell nuclear antigen (PCNA)
antibody, respectively. In addition, mRNA expression of
the adhesion molecule P-selectin was measured. A down-
regulation of P-selectin has recently been identified as
a key mechanism in the cGMP-dependent inhibition of
tissue leukocyte recruitment [19]. Blood creatinine and
urea concentrations, calculated creatinine clearance, and
blood hematocrit served as markers of renal function.
Measurement of systolic blood pressure and proteinuria
Systolic blood pressure was assessed in week 8 and the
days before sacrifice (week 16) in trained conscious ani-
mals, by a tail-cuff method as previously described [14].
The animals were housed individually in metabolic cages
for a 24-hour urine collection 1, 4, 8, 12, and 16 weeks after
anti-thy1 antibody injection. Urinary protein was mea-
sured using a pyrogallol red microtiter plate technique as
previously described [14]. Proteinuria is expressed as mg
protein/24 hours.
Sacrifice
At the end of the experiment, animals were
anesthetized with 0.1 mg ketanest/0.01 mg xylazine
per 100 g body weight (Ketamine 10%) (WDT,
Garbsen, Germany) (Rompun 2%) (Bayer Vital GmbH,
Leverkusen; Germany). Following a midline abdominal
incision, 5 to 10 mL blood was drawn from the abdomi-
nal aorta into etheylenediaminetetraacetic acid (EDTA)-
coated tubes and kidneys were subsequently perfused
with 40 mL ice-cold PBS. Materials and tissues were
subsequently processed as described in the following
sections.
Blood analysis
Plasma and urine creatinine and plasma urea were
measured spectrometrically in enzyme-based assays [15].
The glomerular filtration rate (GFR) was calculated on
the basis of serum and urinary creatinine concentration
and the corresponding urine volume. Hematocrit was de-
termined in blood plasma tubes after a 10-minute cen-
trifugation.
Histology
For histologic examination, cortical tissue was fixed in
10% neutral-buffered formalin or snap-frozen in liquid
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nitrogen. All microscopic examinations were performed
in a blinded fashion. Three lm sections of paraffin-
embedded tissue were stained with periodic acid-Schiff
(PAS) to analyze tubulointerstitial and glomerular fi-
brosis by a computer-based morphometric analysis. Re-
nal sections were examined on a Leica DM LB2 light
microscope (Leica Microsystems, Wetzlar, Germany)
connected to a AxioCam HRc video camera and the
Axiovision 4.00 image analysis system (both Karl Zeiss
Vision GmbH, Mu¨nchen, Germany) using a 10 × 10
orthographic grid overlayed on digital images. The rel-
ative degree of tubulointerstitial fibrotic lesions (i.e.,
matrix deposition, tubular atrophy, and dilation) was cal-
culated in 15 randomly selected cortical areas per animal
observed at ×200 magnification and expressed as per-
centage of the area affected in relation to the total area
analyzed. Glomerular matrix expansion was evaluated
by calculating the relative degree of mesangial matrix
occupying area (in percent) of 15 glomeruli from each
rat.
For analysis of macrophage infiltration, paraffin-
embedded tissues were incubated with a primary mouse
anti-ED1 antibody (Serotec, Oxford, UK) in conjunc-
tion with a standard APAAP technique (DakoCytoma-
tion, Hamburg, Germany), as previously described [14].
Glomerular macrophage infiltration was counted in at
least 15 glomerular sections from each rat, tubulointer-
stitial macrophage infiltration in at least 15 randomly
selected cortical areas per sample observed at ×200
magnification, respectively. Renal cell proliferation was
analyzed using a primary mouse anti-PCNA antibody
(DakoCytomation) and a secondary goat antimouse an-
tibody coupled with the EnvisionTM staining system
(DakoCytomation) [17]. Renal cell proliferation was
evaluated by counting PCNA-positive cells in at least 15
glomerular sections (glomerular cell proliferation) and at
least 15 randomly selected interstitial areas observed at
×200 magnification (tubulointerstitial cell proliferation)
from each rat.
Production of TGF-b1, fibronectin, and PAI-1 protein by
cortical tissue or glomeruli in culture
Glomeruli from individual rats were isolated by a
graded sieving technique (160, 125, and 71 lm mesh metal
sieves), as described previously [6, 15]. For cultures of re-
nal cortical tissue, a piece of cortical tissue was weighed
and minced extensively with a razor blade [15]. Glomeruli
or cortical tissues were suspended in Dulbecco’s mod-
ified Eagle’s medium (DMEM) supplemented with 0.1
U/mL insulin, 100 U/mL penicillin, and 100 lg/mL strep-
tomycin. Glomeruli were cultured at a density of 2000
glomeruli/mL for 48 hours, minced cortical tissue at a
density of 10 mg/mL, respectively. After 48 hours of in-
cubation at 37◦C/5% CO2, supernatants were harvested
and stored at−20◦C until analysis of TGF-b1, fibronectin,
or PAI-1 content.
Effect of Bay 41-2272 on cortical TGF-b1 production
in vitro
To demonstrate that stimulation of the soluble guany-
late cyclase regulates TGF-b production directly and
independently of blood pressure, extensively minced cor-
tical tissue from five normal and five untreated diseased
rats (week 16 after anti-thy1 injection) were resuspended
in DMEM culture medium at a density of 10 mg/mL.
The soluble guanylate cyclase stimulator Bay 41-2272
was added in increasing concentrations: 0, 0.1, 1, 5, and
10 lmol/L. After 48 hours of incubation at 37◦C/5% CO2,
supernatants were harvested and stored at −20◦C un-
til analysis of cortical TGF-b1 production. Two samples
from each animal and Bay 41-2272 concentration were
analyzed.
Measuring TGF-b1, fibronectin, and PAI-1 protein
TGF-b1 content of culture supernatant was measured
after acid activation, using a commercially available
enzyme-linked immunosorbent assay (ELISA) kit (TGF-
b1 DuosetTM) (R&D Systems, Wiesbaden, Germany) ac-
cording to the manufacturer’s instructions. Fibronectin
and PAI-1 levels were measured with modified inhibitory
ELISAs, according to published methods [6, 15]. Three
samples from each rat were analyzed.
Basal and nitric oxide–stimulated glomerular and cortical
cGMP production
Volumes of 150 lL of the resuspended cortical and
glomerular tissues were placed into the wells of a 96-
well microplate and prewarmed at 37◦C/5% CO2 as pre-
viously described [6]. After 1 hour, 20 lL 5 mmol/L
3-isobutyl-1-methylxanthine (IMBX) was added to each
well to block cGMP degradation. After 10 minutes of in-
cubation at 37◦C/5% CO2, the cortical and glomerular
tissues were exposed to 20 lL 1 mmol/L diethylamine-
NONOate (DEA/NO), a fast nitric oxide–releasing
compound (Alexis GmbH, Gru¨nberg, Germany) and in-
cubated for another 10 minutes at 37◦C/5% CO2. To stop
the reaction, the microplate was quickly put on ice, and
20 lL 5% dodecytrimethylammonium bromide was
added to stop the reaction and to facilitate cell lysis. Thus,
results express total (intra- and extracellular) cGMP lev-
els. Lysed cells were stored at −80◦C until analysis [6].
Measurement of cGMP
Cyclic GMP levels in cortical and glomerular lysates
were measured by ELISA (Amersham Pharmacia
Biotech, Freiburg, Germany) according to the manu-
facturer’s instructions. Briefly, samples, standards and
peroxidase-labeled cGMP conjugate were transferred to
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a microplate precoated with a cGMP-specific antibody
[6]. After addition of substrate, optical density was read
at 450 nm using an automated plate reader (MRX II)
(Dynex Technologies, Frankfurt am Main, Germany).
The results are expressed as fmol cGMP per well for
glomerular and cortical lysates.
Measurement of cortical mRNA expression
Cortical total RNA was extracted with TrizolTM
reagent (Gibco BRL, Berlin, Germany) according to
the manufacturer’s instructions. The mRNA expression
was determined by a “two-step” reverse transcription-
polymerase chain reaction (RT-PCR) [6]. A cDNA copy
was created with reverse transcriptase from RNA PCR
Core Kit (Roche, Applied Biosystems, Branchburg, NJ,
USA). Real-time PCR was performed using the Light-
Cycler System and SYBR Green I as dsDNA-binding
dye (Roche Diagnostics GmbH, Mannheim, Germany).
The following primer pairs were used (annealing tem-
perature in parentheses): eNOS sense 5′-TCCAGT
AACACAGACAGTGC-3′, antisense 5′-CAGGAAGT
AAGTGAGAGCCTG-3′ (61◦C); alpha 1 soluble guany-
late cyclase sense 5′-CCACATCAACACAGGCTA
AT-3′, antisense 5′-GAAGTGCAAGGTTCAGTCTC-3′
(62◦C); beta 1 soluble guanylate cyclase sense 5′-CGGA
TGCCACGGTATTGTCT-3′, antisense 5′-CTCCTGG
CTTGACGCACATT-3′ (62◦C); P-selectin sense 5′-AC
CATGACGTGTATCCAGCC-3′, antisense 5′-CCTTC
GTCACACATGAACTG-3′ (61◦C); TGF-b1 sense 5′-
GGTGGCAGGCGAGAGCGCTGA-3′ and anti-
sense 5′-GGCATGGTAGCCCTTGGGCT-3′ (64◦C);
fibronectin sense 5′-GTCCAAATCGGTCATGTTC
CCA-3′, antisense 5′-CGTAATGGGAAACCGTGTAA
GGG-3′ (64◦C); PAI-1 sense 5′-CAGCATGTGGTCC
AGGCCTCCAAA-3′, antisense 5′-TGTGCCGCTCTC
GTTCACCTCGATCT-3′ (64◦C); and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) sense 5′-CCAT
CTTCCAGGAGCGAGAT-3′, antisense 5′-GATGA
CCTTGCCCACAGCCT-3′ (59◦C). For analysis, a
relative quantification method was used as previously
described [6, 20, 21]. Briefly, amplification is described as
N = N0 ∗ ECP (N, number of amplified molecules; N0,
initial number of molecules; E, amplification efficiency;
CP, crossing point deviation expressed as CP =
CPtarget − CPGAPDH). In this quantification method,
measured crossing point is defined as the point at which
the fluorescence rises above the background fluores-
cence. Finally, N0 of the target gene was calculated and
compared relatively to expression of GAPDH mRNA
as housekeeping gene.
Statistical analysis
Data are expressed as mean ± standard error of the
mean (SEM). Statistical analysis between the groups was
performed by one-way analysis of variance (ANOVA)
and a subsequent Mann-Whitney U test. A P value <
0.05 was considered significant.
RESULTS
Body weight, food, and drug intake
At the end of the experiment, body weight had reached
575 ± 21 g in the normal (two-kidney control) and
570 ± 24 g in the uninephrectomized control group
(one-kidney control), respectively. In comparison, final
body weight was significantly lower in all three nephritic
groups (chronic glomerulosclerosis 488 ± 15 g, chronic
glomerulosclerosis + Bay 41-2272 482 ± 11 g, and chronic
glomerulosclerosis + hydralazine 464 ± 13 g) (P < 0.05
vs. controls) (P = NS between the chronic glomeruloscle-
rosis groups), indicating chronic renal disease and insuffi-
ciency. Food and water intakes did not significantly differ
between the groups throughout the experiment (data not
shown).
Blood pressure and proteinuria
As shown in Figure 1, the model of anti-thy1–induced
chronic glomerulonephritis was characterized by a slight
increase in systolic blood pressure 8 and 16 weeks af-
ter disease induction (134 ± 2 mm Hg and 135 ± 1 mm
Hg, respectively) (P < 0.01 vs. controls). Bay 41-2272
treatment lowered blood pressure to 116 ± 3 mm Hg
in week 8 and 116 ± 2 mm Hg in week 16 after anti-
thy1 antibody injection. Hydralazine administration re-
sulted in values of 109 ± 4 mm Hg and 110 ± 3 mm
Hg, respectively (all P < 0.001 vs. chronic glomeruloscle-
rosis) (P = NS for chronic glomerulosclerosis + Bay
41-2272 vs. chronic glomerulosclerosis + hydralazine),
thus achieving a comparable level. Pretreatment pro-
teinuria was markedly increased to a similar degree in
all nephritic groups 7 days after induction of anti-thy1
glomerulosclerosis, indicating the efficacy of the ran-
domization procedure (chronic glomerulosclerosis 148 ±
8 mg/day, chronic glomerulosclerosis + Bay 41-2272
146 ± 7 mg/day, chronic glomerulosclerosis + hydralazine
148 ± 10 mg/day (P = NS). In all three nephritic groups, a
continuous increase in proteinuria was observed. In week
16, proteinuria reached 476 ± 56 mg/day in the untreated
chronic glomerulosclerosis group and 451 ± 70 mg/day in
the chronic glomerulosclerosis + hydralazine group. Pro-
teinuria was slightly lower in the Bay 41-2272–treated
animals, although not significantly (421 ± 42 mg/day)
(P = NS).
Tubulointerstitial matrix accumulation
Characteristic photographs of the animal groups are
shown in Figure 2. Compared to the nonnephritic control
animals, anti-thy1–induced chronic glomerulosclerosis
was characterized by a marked increase in the histologic
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Fig. 1. Effects of Bay 41-2272 and hydralazine on systolic blood pres-
sure 8 and 16 weeks after induction of chronic progressive anti-thy1
glomerulosclerosis (cGS). Treatments were started 7 days after injec-
tion of anti-thy1 antibody into uninephrectomized rats. Nonnephritic
animals without [two-kidney control (2-K Control)] or with uninephrec-
tomy [one-kidney control (1-K Control)] received an injection with sim-
ilar volumes of phosphate-buffered saline (PBS). Blood pressure was
measured in conscious animals using a tail-cuff method. ∗∗∗P < 0.001
vs. chronic glomerulosclerosis.
tubulointerstitial matrix score (39.9 ± 4.8%) and the pro-
tein expression of TGF-b1 (296 ± 24 pg/mL), fibronectin
(7296 ± 760 ng/mL), and PAI-1 (241 ± 12 ng/mL) (all P
< 0.01 vs. two-kidney and one-kidney control) (Fig. 3).
The mRNA expression of TGF-b1 was elevated 9.4-fold,
the mRNA expression of fibronectin and PAI-1 increased
10.9- and 13.1-fold, respectively (all P < 0.01 vs. two-
kidney and one-kidney control). Administration of Bay
41-2272 significantly reduced histologic matrix accumula-
tion (−40.67%), protein and mRNA expression of TGF-
b1 [−40.6% (P < 0.05 vs. chronic glomerulosclerosis +
hydralazine), −37.3%], fibronectin [−50.6% (P < 0.05
vs. chronic glomerulosclerosis + hydralazine), −59.7%],
and PAI-1 (−15.1%, −55.2%), respectively (all P < 0.05
vs. chronic glomerulosclerosis) (Fig. 3), while treatment
with hydralazine only slightly and not significantly low-
ered the tubulointerstitial disease severity in the chronic
anti-thy1 animals.
Expression and activity of the tubulointerstitial nitric
oxide–cGMP signaling cascade
In comparison to the two-kidney and one-kidney con-
trol groups, anti-thy1–induced chronic glomeruloscle-
rosis showed a marked 2.8-fold and 3.2-fold increase
in the mRNA expression of alpha 1 (P < 0.05) and
beta 1 soluble guanylate cyclase (P < 0.01) (Fig. 4A
and B). Tubulointerstitial eNOS mRNA expression was
slightly higher in the diseased animals (1.4-fold) (P =
0.10), but not further significantly altered by Bay 41-2272
or hydralazine treatment. While basal tubulointerstitial
cGMP production did not differ between the groups, the
nitric oxide–stimulated cGMP production was 2.7-fold
higher in the chronic anti-thy1 group than in normal con-
trols (Fig. 4C and D). Administration of Bay 41-2272
did not significantly alter the expression of the soluble
guanylate cyclase, but resulted in a significantly higher
nitric oxide–stimulated tubulointerstitial cGMP produc-
tion when compared to the untreated anti-thy1 animals
(533 ± 126 fmol/well vs. 282 ± 41 fmol/well) (P < 0.05)
(Fig. 4). Treatment with hydralazine did not significantly
affect expression and activity of the soluble guanylate cy-
clase.
Glomerular matrix accumulation
The glomerular matrix protein expression in anti-thy1-
induced chronic glomerulosclerosis was characterized by
an increase in histologic matrix score (48.7 ± 3.5%)
and protein expression of TGF-b1 (173 ± 24 pg/mL),
fibronectin (11229 ± 1255 ng/mL), and PAI-1 (351 ±
32 ng/mL) (P < 0.01 vs. two-kidney and one-kidney con-
trol) (Fig. 5). While Bay 41-2272 significantly lowered
histologic matrix accumulation (31.5 ± 1.8%) and TGF-
b1 (124 ± 12 pg/mL) and fibronectin protein expression
(5580 ± 735 ng/mL) (all P < 0.05 vs. chronic glomeru-
losclerosis) (Fig. 7), treatment with hydralazine did not
significantly affect glomerular matrix protein expression
and accumulation. Glomerular PAI-1 protein expression
was reduced by Bay 41-2272 as well (299 ± 15 ng/mL),
but this did not reach statistical significance.
Activity of the glomerular nitric oxide–cGMP
signaling cascade
In comparison to the nonnephritic control animals,
basal and nitric oxide–stimulated glomerular cGMP pro-
duction were lower in the untreated chronic anti-thy1
animals [−36%) (P = NS), −51% (P < 0.05 vs. two-
kidney control, respectively] (Fig. 6). Treatment with Bay
41-2272 increased basal (12 ± 2 vs. 9 ± 1 fmol/well in
chronic glomerulosclerosis) (P = 0.17) and nitric oxide–
stimulated cGMP production (59 ± 8 vs. 32 ± 4 fmol/well
in chronic glomerulosclerosis) (P < 0.01) compared to
the untreated chronic anti-thy1 group. In contrast, hy-
dralazine administration did not affect basal and nitric
oxide–stimulated glomerular cGMP synthesis.
Plasma markers of renal function
As shown in Table 1, animals with chronic anti-thy1
glomerulosclerosis showed significant increases in plasma
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Fig. 2. Effects of Bay 41-2272 and hydralazine on the histologic picture 16 weeks after induction of chronic progressive anti-thy1 glomerulosclerosis
(cGS). Treatments were started 7 days after injection of anti-thy1 antibody into uninephrectomized rats. Shown are characteristic periodic acid–Schiff
(PAS)-stained renal sections from (A) a nonnephritic animal without [two-kidney control (2-K Control)] and (B) with uninephrectomy [one-kidney
control (1-K Control)] and (C) an animal with anti-thy1–induced chronic glomerulosclerosis without and with Bay 41-2272 (D) or with hydralazine
treatment (E) (magnification ×200).
creatinine and urea levels, while creatinine clearances
and blood hematocrit levels were decreased (all P <
0.01 vs. one-kidney control). Corresponding to the his-
tologic and molecular results on renal matrix expan-
sion, administration of Bay 41-2272 significantly lowered
plasma creatinine and urea levels, while creatinine clear-
ances and blood hematocrit levels were preserved (all
P < 0.05 vs. chronic glomerulosclerosis). In contrast, re-
nal function was not significantly affected by hydralazine
treatment.
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Fig. 3. Effects of Bay 41-2272 and hydralazine on tubulointerstitial matrix protein expression 16 weeks after induction of chronic progressive
anti-thy1 glomerulosclerosis (cGS). Shown are tubulointerstitial matrix accumulation (A) and protein expression of transforming growth factor-b1
(TGF-b1) (B), fibronectin (C), and plasminogen activator inhibitor type 1 (PAI-1) (D). Treatments were started 7 days after injection of anti-thy1
antibody into uninephrectomized rats. Nonnephritic animals without [two-kidney control (2-K Control)] and with uninephrectomy [one-kidney
control (1-K Control)] received a phosphate-buffered saline (PBS) injection. The relative degree of matrix accumulation was calculated by computer-
based morphometric analysis. Matrix protein production was determined in extensively minced individual cortical tissues cultured at a density of
10 mg/mL for 48 hours. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 vs. chronic glomerulosclerosis; #P < 0.05; ##P < 0.01 vs. chronic glomerulosclerosis +
hydralazine.
Mechanism underlying the blood-pressure independent
renoprotective effects of Bay 41-2272
Renal macrophage infiltration, P-selectin expression,
cell proliferation, and action of Bay 41-2272 on corti-
cal TGF-b1 production in culture were analyzed. As
shown in Figure 7, chronic progressive anti-thy1 glomeru-
losclerosis was characterized by a marked tubulointersti-
tial and glomerular macrophage infiltration and cell pro-
liferation. The number of ED1–positive cells increased
7.4-fold at the tubulointerstitial level and 3.0-fold at
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Fig. 4. Tubulointerstitial mRNA expression of alpha 1 soluble guanylate cyclase (alpha 1 sGC) (A) and beta 1 soluble guanylate cyclase (B) and
basal (C) and nitric oxide stimulated (D) cortical cyclic 3′,5′-guanosine monophosphate (cGMP) synthesis in rats 16 weeks after induction of chronic
progressive anti-thy1 glomerulosclerosis (cGS). Treatment with Bay 41-2272 or hydralazine was started 7 days after injection of anti-thy1 antibody
into uninephrectomized rats. Nonnephritic animals without [two-kidney control (2-K Control)] and with uninephrectomy [one-kidney control (1-K
Control)] received a phosphate-buffered saline (PBS) injection. mRNA was analyzed by a real-time polymerase chain reaction (PCR) method using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene. mRNA expression is shown as a percentage of the untreated chronic
anti-thy1 animals ( = 100%). cGMP generation was measured by enzyme-linked immunosorbent assay (ELISA) in cortical tissue harvested from
individual animals in the presence or absence of the nitric oxide donor diethylamine (DEA). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 vs. two-kidney
and one-kidney control; # P < 0.05 vs. chronic glomerulosclerosis.
the glomerular level, while PCNA-positive tubuloint-
erstitial cells were elevated by 21.1-fold and PCNA-
positive glomerular cells by 2.5-fold, respectively (all P <
0.001 vs. one-kidney control). Treatment with Bay 41-
2272 markedly reduced tubulointerstitial infiltration with
macrophages (35 ± 4 vs. 58 ± 5 ED1-positive cells/section
in chronic glomerulosclerosis) and proliferation of inter-
stitial cells (29 ± 4 vs. 46 ± 4 PCNA-positive cells/section
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Fig. 5. Effects of Bay 41-2272 and hydralazine on glomerular matrix protein expression 16 weeks after induction of chronic-progressive anti-thy1
glomerulosclerosis (cGS). Shown are glomerular matrix accumulation (A) and protein expression of transforming growth factor-b1 (TGF-b1) (B),
fibronectin (C), and plasminogen activator inhibitor type 1 (PAI-1) (D). Treatments were started 7 days after injection of anti-thy1 antibody into
uninephrectomized rats. Nonnephritic animals without [two-kidney control (2-K Control)] and with uninephrectomy [one-kidney control (1-K
Control)] received a phosphate-buffered saline (PBS) injection. The relative degree of matrix expansion was calculated by a computer-based
morphometric analysis on periodic acid-Schiff (PAS)-stained slides. Glomeruli were harvested from individual animals and cultured at a density of
2000 per mL for 48 hours. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001 vs. chronic glomerulosclerosis; ##P < 0.01 vs. chronic glomerulosclerosis + hydralazine.
in chronic glomerulosclerosis). In addition, the glomeru-
lar number of macrophages (1.4 ± 0.2 vs. 2.6 ± 0.3 ED-1–
positive cells/section in chronic glomerulosclerosis) and
proliferating cells (1.2 ± 0.1 vs. 2.2 ± 0.3 PCNA-positive
cells/section in chronic glomerulosclerosis) were found
to be reduced by Bay 41-2272 (all P < 0.01 vs. chronic
glomerulosclerosis and P < 0.05 vs. chronic glomeru-
losclerosis + hydralazine). Hydralazine therapy was
without a significant influence on tubulointerstitial and
glomerular macrophage infiltration and cell proliferation
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Fig. 6. Basal (A) and nitric oxide stimulated (B) glomerular cyclic 3′,5′-guanosine monophosphate (cGMP) synthesis 16 weeks after induction of
chronic progressive anti-thy1 glomerulosclerosis (cGS). Treatment with Bay 41-2272 and hydralazine was started 7 days after injection of anti-thy1
antibody into uninephrectomized rats. Nonnephritic animals without [two-kidney control (2-K Control)] and with uninephrectomy [one-kidney
control (1-K Control)] received a phosphate-buffered saline (PBS) injection. cGMP generation was measured by enzyme-linked immunosorbent
assay (ELISA) in glomerular tissue harvested from individual animals in the presence or absence of the nitric acid donor diethylamine (DEA)/nitric
oxide. ∗P < 0.05 vs. chronic glomerulosclerosis.
Table 1. Effects of Bay 41-2272 and hydralazine on markers of renal function 16 weeks after induction of chronic-progressive anti-thy1
glomerulosclerosis
Group/parameter Creatinine mg/dL Urea mg/dL GFR/100 g body weight mL/min Hematocrit%
Two-kidney control 0.39 ± 0.03 44 ± 3 0.63 ± 0.05 49 ± 1
One-kidney control 0.47 ± 0.01 51 ± 3 0.53 ± 0.02 48 ± 1
Chronic glomerulosclerosis 1.89 ± 0.38a 187 ± 45a 0.25 ± 0.04a 41 ± 2a
Chronic glomerulosclerosis + Bay 41 - 2272 0.74 ± 0.08b,c 85 ± 42b,c 0.48 ± 0.06b 46 ± 1b,c
Chronic glomerulosclerosis + hydralazine 1.51 ± 0.42 139 ± 86 0.34 ± 0.06 40 ± 2
GFR is glomerular filtration rate. Plasma creatinine and urea levels and creatinine clearance served as markers of the excretory kidney function and blood hematocrit
for the renal endocrine, erythropoietin-producing capacity. Nonnephritic animals without (two-kidney control) and with uninephrectomy (one-kidney control) received
a phosphate-buffered saline (PBS) injection.
aP < 0.01 vs. one-kidney control; bP < 0.05 vs. chronic glomerulosclerosis; cP < 0.05 vs. chronic glomerulosclerosis + hydralazine.
(Fig. 7). In parallel with the renal macrophage number,
cortical P-selectin mRNA expression increased 7.7-fold
(P < 0.001) in the untreated chronic anti-thy animals as
compared to the normal controls. Cortical P-selectin ex-
pression was significantly reduced by Bay 41-2272 (−47 ±
8%) (P < 0.05 vs. chronic glomerulosclerosis), but not by
hydralazine treatment (−19 ± 23%) (P = NS vs. chronic
glomerulosclerosis). In cultured cortical tissue harvested
from chronic anti-thy1 animals, the presence of 0.1, 1, 5,
and 10 lmol/L Bay 41-2272 reduced dose-dependently
48-hour TGF-b1 protein production by 12.4%, 14.0%,
20.1%, and 19.0% (all P < 0.05 vs. without Bay 41-2272).
In cortical tissues cultures of normal control animals, the
reduction achieved by incubation with Bay 41-2272 were
by 18.1%, 24.2%, 18.9%, and 22.1% (all P < 0.05 vs. with-
out Bay 41-2272), respectively.
In sum, the present study shows that nitric oxide–
cGMP signal transduction is discordantly altered in the
progressive model of anti-thy1–induced chronic glomeru-
losclerosis. While the tubulointerstitial soluble guanylate
activity was markedly up-regulated, its glomerular
activity was diminished. Administration of Bay 41-
2272 significantly increased both tubulointerstitial and
glomerular soluble guanylate catalase activity and sub-
sequently limited the progressive course of this model
toward glomerulosclerosis, tubulointerstitial fibrosis, and
renal insufficiency in a blood pressure–independent
manner.
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Fig. 7. Effects of Bay 41-2272 and hydralazine on tubulointerstitial and glomerular macrophage infiltration (A and B) and cell proliferation (C and
D) 16 weeks after induction of chronic progressive anti-thy1 glomerulosclerosis (cGS). Analysis was performed using a primary ED1 antibody for
macrophages and a primary proliferating cell nuclear antigen (PCNA) antibody for proliferating cells. Data are expressed as cells per cortical section
observed at ×200 magnification and per glomerular cross-section. ∗∗P < 0.01 vs. chronic glomerulosclerosis; #P < 0.05 vs. chronic glomerulosclerosis
+ hydralazine.
DISCUSSION
The main precursor for the endogenous synthesis of
nitric oxide is the amino acid L-arginine, supply with the
food can be rate-limiting [22, 23]. With regard to acute
and chronic renal diseases, nitric oxide serves not only as
key messenger in regulating vascular tone, integrity of the
endothelial cell layer and neuronal transmission, but also
as key effector molecule of the immune system. Research
over the last years has revealed that increasing the dietary
L-arginine supply to activate renal nitric oxide pathways
can both increase and decrease TGF-b overexpression
and matrix protein accumulation in experimental kidney
disease [22, 23]. Harmful actions of L-arginine supple-
mentation have been documented when inducible NOS
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(iNOS) were operating and the high concentrations of ni-
tric oxide produced acted primarily as a destructive free
radical in immune-mediated renal tissue injury [24, 25].
In contrast, beneficial actions from L-arginine adminis-
tration have been described in models of kidney disease
in which endothelial dysfunction and subsequent hyper-
tensive tissue damage play a predominant role in TGF-b
overproduction and matrix protein expansion [22, 23].
In hypertensive tissue injury, L-arginine enhances insuffi-
cient endothelial nitric oxide production and, something
that is of relevance to this investigation, thereby enhances
insufficient nitric oxide–dependent synthesis and action
of cGMP as its second messenger molecule.
In parallel to increased glomerular expression and
activity of soluble guanylate cyclase in acute anti-
thy1 glomerulonephritis [6], tubulointerstitial solu-
ble guanylate cyclase mRNA expression and nitric
oxide–dependent cGMP production were significantly
up-regulated in the presence of marked tubulointersti-
tial fibrosis 16 weeks after induction of the progressive
anti-thy1 glomerulosclerosis. Without altering the solu-
ble guanylate cyclase expression, Bay 41-2272 treatment
enhanced the cGMP production of cortical tissue in re-
sponse to nitric oxide and subsequently markedly limited
the tubulointerstitial progression in this model as shown
by reduced histologic tubulointerstitial fibrosis and ex-
pression of TGF-b1, fibronectin, and PAI-1. In addition,
administration of the soluble guanylate cyclase stimula-
tor lowered blood creatinine and urea concentrations
and increased GFR and hematocrit levels, underscor-
ing that the morphologic and molecular tubulointerstitial
benefits achieved went along with improved renal func-
tion. Thus, the present study in progressive anti-thy1–
induced chronic glomerulosclerosis confirms the critical
role of the soluble guanylate cyclase enzyme and nitric
oxide–dependent cGMP production in pathologic renal
matrix accumulation as previously revealed in the acute
anti-thy1 model [6]. Furthermore, the important function
of the soluble guanylate cyclase enzyme in fibrotic kid-
ney disorders is thereby now expanded from glomerular
to tubulointerstitial TGF-b overexpression and matrix
expansion, as well as from acute, reversible to chronic
progressive renal disease.
At the glomerular level and in the presence of chronic
glomerulosclerosis, the cGMP production in response
to nitric oxide was found to be markedly decreased 16
weeks after disease induction. This contrasts to tubuloin-
terstitial nitric oxide–cGMP signaling in the same model
at the same time, but also to the strong up-regulation
of glomerular soluble guanylate cyclase activity recently
documented in acute anti-thy1 glomerulonephritis [6].
The glomerular findings in the acute and chronic anti-thy1
models together suggest that the transition from acute
to chronic glomerular TGF-b overexpression and matrix
protein accumulation is paralleled by the development
of an absolute insufficiency in nitric oxide–cGMP signal
transduction. Interestingly, Bay 41-2272 treatment also
improved glomerular cGMP production under these cir-
cumstances and thereby limited the degree of glomeru-
losclerosis.
In general, nitric oxide deficiency is understood as an
absolute or relative insufficiency in the synthesis of nitric
oxide [22, 23]. The decreased glomerular cGMP synthe-
sis in response to nitric oxide now documented in chronic
anti-thy1 glomerulosclerosis shows that an impairment of
nitric oxide–cGMP signal transduction can be a relevant
mechanism as well. This concept is supported by several
other recent studies documenting a decrease in the activ-
ity of vascular soluble guanylate cyclase in models appear-
ing functionally as nitric oxide deficiency. These models
include spontaneously hypertensive rats, aging, myocar-
dial infarction, angiotensin II infusion, lead-induced hy-
pertension, and diabetic Goto-Kakizate rats [26–31].
Although Bay 41-2272 treatment markedly lowered
systolic blood pressure, the mechanism by which this
compound slowed the progressive course of anti-thy1–
induced chronic glomerulosclerosis appeared to be at
least partially independent of blood pressure reduc-
tion. Several pathways were found to be involved. First,
there was a reduction in renal macrophage infiltration.
Macrophages can serve as an important source of TGF-b
overexpression and thereby as amplifier of renal matrix
protein expression and accumulation. The decrease in re-
nal macrophage number through Bay 41-2272 was asso-
ciated with a down-regulation of the adhesion molecule
P-selectin which is regulated directly by cGMP as recently
reported [19]. Second, there was a reduction in renal cell
proliferation. In many kidney diseases, renal cell prolif-
eration precedes extracellular matrix protein expansion.
An inhibitory effect of enhancing cGMP production has
been previously reported for renal cell proliferation in
vivo and in vitro [32] [abstract; Hohenstein et al, J Am
Soc Nephrol 14:63A, 2003]. Third, there was a reduction
in TGF-b1 protein production as shown by the inhibitory
action of Bay 41-2272 on cortical tissue in culture. This
finding is consistent with previous studies documenting
a direct inhibitory effect of increasing cGMP on renal
TGF-b expression and activation in nephritic glomeruli
and renal cells exposed to high glucose [6, 33].
The antifibrotic effects of Bay 41-2272 seen in the
acute and chronic-progressive anti-thy1 models suggest
that pharmacologic enhancement of soluble guanylate
cyclase activity may be a reasonable approach toward
overcoming the documented limitations of L-arginine
supplementation or nitric oxide donation in treating nitric
oxide deficiency in renal disease [22, 23, 34, 35]. The use
of L-arginine is not only obstructed by the potential syn-
thesis of cytotoxic amounts of nitric oxide via inducible
NOS, but also by the generation of agmatine, proline,
and polyamines via alternative L-arginine–metabolizing
60 Wang et al: Soluble guanylate cyclase in anti-thy1 glomerulosclerosis
pathways [22, 23, 25]. All these endogenous L-arginine
metabolites are involved in renal tissue repair through
different, partly opposing mechanisms [23]. The use of
pharmacologic nitric oxide donors such as molsidomine,
whose active metabolite SIN-1 releases nitric oxide spon-
taneously, therefore has been advocated [36]. However,
this approach leads to a rather unspecific release of nitric
oxide across the whole body, is prone to tachyphylaxis
and has been linked to an unwanted pro-oxidant activity
[37]. In contrast, the new class of soluble guanylate cy-
clase enhancers such as Bay 41-2272 act functionally and
spatially in a very specific manner on the L-arginine–nitric
oxide–cGMP cascade [8, 9], since they amplify the cGMP
signal exactly at that subcellular place where it is natu-
rally generated and the further cGMP effector pathways
are already lined up. In addition, Bay 41-2272 effects on
soluble guanylate cyclase activity show no tachyphylaxis
[9].
Progression in the anti-thy1–induced chronic glomeru-
losclerosis model is not primarily immune-mediated. The
features of advancing tubulointerstitial fibrosis, tubular
atrophy, round cell infiltration, and loss of renal func-
tion are shared by many other chronic kidney diseases,
which is in a line with the concept that a common final
pathway underlies the advance of renal disease [1, 14].
Therefore, the findings of this study may well be relevant
for other progressive kidney disorders, such as diabetic
and hypertensive nephropathy. Further studies will show
whether activation of soluble guanylate cyclase counter-
acts fibrosis in these diseases and whether pharmaco-
logic soluble guanylate cyclase stimulation will slow their
progression toward end-stage renal disease in a blood
pressure–independent manner. Beyond this, our tandem
study on the role of soluble guanylate cyclase in acute
and chronic progressive anti-thy1–induced renal disease
may be of relevance for the understanding and potential
future treatment of human forms of glomerulonephritis,
such as IgA nephropathy.
CONCLUSION
The present study shows that the activity of soluble
guanylate cyclase is markedly up-regulated in tubuloint-
erstitial fibrosis of anti-thy1–induced chronic renal fibro-
sis, while it is reduced in its glomerulosclerosis. Specific
stimulation of soluble guanylate cyclase signaling by Bay
41-2272 significantly limits the course of this progressive
model toward tubulointerstitial fibrosis and impaired re-
nal function at least partially in a manner independent
of systolic blood pressure. The results suggest that acti-
vation of the soluble guanylate cyclase enzyme and sub-
sequent cGMP production represent an important antifi-
brotic pathway in the progression of renal disease.
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